Evidence check: LDL in the context of menopause

During menopause, declining estrogen levels shift the lipid profile: LDL cholesterol typically rises, while HDL often remains stable or slightly decreases. This increase is a normal physiological change but elevates cardiovascular risk. Direct, evidence-based links between specific genetic variants (e.g., APOE, PCSK9) and LDL rise in menopause are weak. Most studies are observational with moderate effect sizes. Consumer tests like MyBody-X may offer SNP-based risk scores, but these are not sufficiently validated for predicting menopause-related LDL changes. Clinically, regular lipid monitoring, lifestyle modifications (diet, exercise), and possibly hormone therapy or statins are more relevant. The evidence for genetic testing in this context is 'human-moderate' to 'mixed'. Caveat: Elevated LDL in menopause warrants medical evaluation, not solely genetic interpretation.